Complex Regional Pain Syndrome Type 1 carries an estimated 65,000 new U.S. diagnoses each year, yet the clinical trial infrastructure to study it rigorously has been almost nonexistent — which makes the design choices inside Ambros Therapeutics’ CRPS-RISE trial more consequential than the first-patient-dosed milestone itself. Neridronate is a bisphosphonate already approved in Italy for CRPS, with prior randomized data showing VAS pain scores diverge sharply from placebo by day 30. The U.S. pivotal program is not simply replicating that work — it is layering a precision-medicine filter on top of it, and that filter will define whether the trial succeeds or sets a precedent others have to follow.
CRPS-RISE enrolls approximately 270 participants, randomized 1:1, but the eligibility criteria are deliberately narrow. Participants must have warm-phase CRPS-1 of six months’ duration or less, a confirmed precipitating event, moderate-to-severe pain, and — critically — a positive triple-phase bone scan. That last requirement operationalizes a biological hypothesis: neridronate’s activity is most relevant in the inflammatory warm phase, and the bone scan serves as a proxy for active skeletal involvement. Four IV infusions over 10 days deliver a 400 mg total dose, with the primary endpoint being NRS pain change at week 12. Short treatment window, tightly defined population, single primary endpoint. The FDA has already signaled, based on direct interactions, that positive results from this single trial could support a U.S. approval — a meaningful concession given the agency’s typical preference for two pivotal studies, and one the Breakthrough Therapy designation granted in December 2016 helped negotiate over nearly a decade of dialogue.
The strategic bet here is that enriching the population improves signal-to-noise enough to power a 270-person trial to a convincing result. That bet is defensible — prior Italian trial data showed 65.9% of neridronate-treated patients achieving clinically meaningful pain reduction versus placebo — but it introduces a real regulatory question downstream: if approval is granted in warm CRPS-1 patients who are bone-scan positive, the labeled population will be a subset of the broader condition, and payer coverage will almost certainly follow the label’s edges. Physicians managing patients who don’t meet those criteria will still be on their own. That gap is not a flaw in the trial design; it is the honest price of running a precision-enrollment study in a rare, heterogeneous disease.
The number to watch as enrollment progresses is screen-failure rate. Triple-phase bone scans are not universally available, and many CRPS-1 patients present late or without a clearly documented precipitating event. If screen failures run high, the 270-participant target becomes harder to reach within any reasonable window, and the trial’s elegant design becomes a recruitment liability. Ambros has built in a long-term outcomes registry and an open-label rescue arm for completers — both of which help retention — but the front-end screening burden is where this program is most exposed.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
